Health Services Research & Development

Veterans Crisis Line Badge
Go to the ORD website
Go to the QUERI website

HSR&D Citation Abstracts

Search | Search by Center | Search by Source | Keywords in Title

Sitlinger A, Shelby RA, Van Denburg AN, White H, Edmond SN, Marcom PK, Bosworth HB, Keefe FJ, Kimmick GG. Higher symptom burden is associated with lower function in women taking adjuvant endocrine therapy for breast cancer. Journal of geriatric oncology. 2019 Mar 1; 10(2):317-321.
PubMed logo Search for Abstract from PubMed
(This link leaves the website of VA HSR&D.)

Abstract: OBJECTIVE: To explore the impact of symptoms on physical function in women on adjuvant endocrine therapy for breast cancer. METHODS: Eligible women were postmenopausal, had hormone receptor positive, stage I-IIIA breast cancer, completed surgery, chemotherapy, radiation, and on adjuvant endocrine therapy. At a routine follow-up visit, women (N?=?107) completed standardized symptom measures: Brief Fatigue Inventory, Brief Pain Inventory, Menopause Specific Quality of Life Questionnaire, Functional Assessment of Cancer Therapy Neurotoxicity scales. Two performance measures assessed function: grip strength (Jamar dynamometer; n?=?71) and timed get-up-and-go (TUG; n?=?103). Analyses were performed with an overall symptom composite score. Correlations and multiple linear regression analyses were performed to test adverse effects on physical function. RESULTS: The mean age was 64?years (range 45-84), 81% white, 84% on an aromatase inhibitor, and on endocrine therapy for mean 35?months (range 1-130?months). Dominant hand grip strength was inversely correlated with symptom composite scores (r?=?-0.29, p?=?.02). Slower TUG was positively correlated with higher Charlson comorbidity level (r?=?0.36, p?